Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
201.98
-0.84 (-0.41%)
Dec 18, 2025, 9:33 AM EST - Market open
Ascendis Pharma Revenue
Ascendis Pharma had revenue of 213.63M EUR in the quarter ending September 30, 2025, with 269.40% growth. This brings the company's revenue in the last twelve months to 646.55M, up 97.46% year-over-year. In the year 2024, Ascendis Pharma had annual revenue of 363.64M with 36.34% growth.
Revenue (ttm)
646.55M EUR
Revenue Growth
+97.46%
P/S Ratio
16.11
Revenue / Employee
635,740 EUR
Employees
1,017
Market Cap
12.34B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.64M | 96.92M | 36.34% |
| Dec 31, 2023 | 266.72M | 215.54M | 421.20% |
| Jan 1, 2023 | 51.17M | 43.40M | 557.93% |
| Dec 31, 2021 | 7.78M | 825.00K | 11.87% |
| Dec 31, 2020 | 6.95M | -6.42M | -48.01% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ASND News
- 3 days ago - Here's My Prediction For Who Could Acquire Ascendis Pharma - Seeking Alpha
- 6 days ago - Eight stock picks to play one of the healthiest corners of the market - Market Watch
- 7 days ago - High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth - Seeking Alpha
- 13 days ago - Ascendis: Q3 Results Validate The TransCon Platform - Seeking Alpha
- 19 days ago - Ascendis Pharma Hit By FDA Delay As TransCon CNP Decision Slips To 2026 - Benzinga
- 22 days ago - US FDA extends review of Ascendis Pharma's therapy for children with dwarfism - Reuters
- 22 days ago - Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia - GlobeNewsWire
- 4 weeks ago - Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics - GlobeNewsWire